SARS-CoV-2 (COVID-19) as a Predictor of Neuroinflammation and Neurodegeneration: Potential Treatment Strategies.

Abstract

The SARS-CoV-2 (COVID-19) pandemic has attracted attention to the challenge of neuroinflammation as an unavoidable component of viral infections. Acute neuroinflammatory responses include activation of resident tissue macrophages in the CNS followed by release of a variety of cytokines and chemokines associated with activation of oxidative stress and delayed neuron damage. This makes the search for treatments with indirect anti-inflammatory properties relevant. From this point of view, attention is focused on further study of the treatment of patients with COVID-19 with dipyridamole (Curantil) which, having antiviral and anti-inflammatory effects, can inhibit acute inflammatory activity and progression of fibrosis, is a drug with potential, especially among patients with early increases in the D-dimer concentration and severe signs of microangiopathy.

• Authors: M V Putilina, D V Grishin
• Journal: Neuroscience and behavioral physiology (Neurosci Behav Physiol) Vol. 51 Issue 5 Pg. 577-582 ( 2021) ISSN: 1573-899X [Electronic] United States
• PMID: 34176996 (Publication Type: Journal Article)
• Copyright: © Springer Science+Business Media, LLC, part of Springer Nature 2021.